Navigation Links
Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans
Date:12/21/2009

own risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings w
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Cardiome To Release Third Quarter Results
5. Cardiome Initiates Phase 1 Study for GED-aPC
6. Cardiome Updates Guidance
7. Cardiome to Hold Investor Update Call
8. Cardiome And Astellas Announce Regulatory Update
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. Cardiome To Release 2007 Results
11. Cardiome To Release 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Hospital announced today it is teaming up with the ... the Presenting Sponsor of the 2014-15 and 2015-16 seasons, ... partner. As the Presenting Sponsor for the next two ... inclusion on all Lightning advertising campaigns and materials throughout ... sponsorship partner of the Lightning since 2011, and it ...
(Date:9/16/2014)... of dairy food may reduce the risk of heart ... have not traditionally formed part of the diet. ... Emeritus Professor Mark Wahlqvist from Monash University,s Department of ... considered the role increased consumption of dairy foods had ... , "In a dominantly Chinese food culture, unaccustomed ...
(Date:9/16/2014)... who have had children (parous women) appear to ... breast cancer, the subtype that carries a higher ... of African ancestry. A similar relationship was ... between childbearing and increased risk of estrogen receptor-negative ... the women who had never breastfed. These findings, ...
(Date:9/16/2014)... have developed a new cocktail that is highly ... pluripotent stem cells. , Regenerative medicine is a ... lost or damaged cells, tissues or organs through ... embryos can trigger ethical concerns, a good solution ... state using a combination of reprogramming factors. ...
(Date:9/16/2014)... Terminsurancevirginia.com has released a new blog ... life insurance for obese clients. , Obese clients ... quotes. It is unlikely for applicants to be denied ... life insurance costs. , Having life insurance is ... Life insurance is available as temporary or permanent coverage ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2Health News:Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells 2Health News:Obese Clients Can Find Affordable No Exam Term Life Insurance at Terminsurancevirginia.com! 2
... HealthDay Reporter , MONDAY, Feb. 7 (HealthDay News) -- ... may be less likely to develop a tough-to-treat brain ... It,s not clear how this knowledge might improve prevention ... said the findings pave the way for further research. ...
... Feb. 7 (HealthDay News) -- The number of Americans ... economy, statistics released Monday suggest. Last year, there ... country, up five percent from 2009, the American Society ... cosmetic surgical procedures and 11.6 cosmetic minimally-invasive procedures. The ...
... State for Research and Emilio Botn, president of ... Finantial City (located in Boadilla del Monte) the ... included in PESA (Progression of Early Subclinical Atherosclerosis) ... Center for Cardiovascular Research (CNIC) and Grupo Santander ...
... radiation from cardiac imaging and other procedures after a ... cancer, found a new study published in CMAJ ... only) http://www.cmaj.ca/embargo/cmaj100463.pdf . The use of procedures ... angiography and nuclear scans, is increasing which has led ...
... Geneva, Switzerland. Following the publication of several media reports ... grants financed by the Global Fund to Fight AIDS, ... all donors and governments to continue their funding. ... instrument which attracts, manages and disburses resources to prevent ...
... diseases. Gene therapy direct replacement of mutant genes by ... defects. Now a research team based at the Medical Center ... Carsten Rudolph, has taken a new approach that avoids DNA ... modification of mRNAs (the metabolically active molecules derived from genomic ...
Cached Medicine News:Health News:Allergies Linked to Lower Brain Cancer Rate in Study 2Health News:Allergies Linked to Lower Brain Cancer Rate in Study 3Health News:As Economy Picks Up, So Do Number of Nips & Tucks 2Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 2Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 3Health News:Risk of cancer increases with exposure to low-dose radiation 2Health News:Media reports ignore that Global Fund resources deliver tremendous results in the fight against AIDS 2Health News:Save messengers -- modified mRNAs open up new therapeutic possibilities 2
(Date:9/16/2014)... , Sept. 16, 2014  Synereca Pharmaceutics, ... novel orally active drugs that restore or ... today a $1.4 million convertible debt financing. ... life sciences accelerator Accele Biopharma, Inc., led ... a nationally recognized private not-for-profit corporation focused ...
(Date:9/16/2014)... , Sept. 16, 2014  DNAtrix, Inc., ... the first patient was treated with the company,s ... gamma interferon in a randomized, multicenter, open-label Phase ... "DNAtrix, in collaboration with leading neurosurgeons and ... the initiation of our randomized Phase Ib study ...
(Date:9/16/2014)... 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage ... pain, announced today that it has entered into an ... a series of animal studies for levorphanol, the active ... form of levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC ... Dr. Pasternak said, "Levorphanol is a unique opioid ...
Breaking Medicine Technology:Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... Ladin, director of the Pew Health Group,s Antibiotics ... the bipartisan, bicameral Generating Antibiotic Incentives Now (GAIN) ... and Sen. Bob Corker (R-Tenn.).  The bill is ... to incentivize the creation of new antibiotics to ...
... Oct. 19, 2011 The maker of ... aid with a proprietary formula, has succeeded in protecting ... according to the company president, Holly Rosenthal. Under the ... Inc., maker of MidNite Sleep Remedy, and Contract Pharmacal ...
Cached Medicine Technology:Popular Sleep Supplement Brand Settles Patent Infringement Suit Against Store Brand Manufacturer 2
... best value in high performance electronic pipetting!, ... design reduce hand fatigue and strain , ... ejector , Color coding for easy volume ... greater performance use Hamilton AdvanTip Low Retention ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... ejection with long, lever tip ejector, Color ... tips or for greater performance use Hamilton ...
... is a major step forward in ... handling system - with one universal ... modules. All five single channel and ... one handle. The lightweight handle is ...
... a system that measures the sedimentation ... rate may be relevant as input ... rate is measured in a batch ... in high-volume settings such as hospitals ...
Medicine Products: